Article
CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X
3 Sept 2015
Abstract excerpt
Current antiviral therapies cannot cure hepatitis B virus (HBV) infection; successful HBV eradication would require inactivation of the viral genome, which primarily persists in host cells as episomal covalently closed circular DNA (cccDNA) and, to a lesser extent, as chromosomally integrated sequences. However, novel designer enzymes, such as the CRISPR/Cas9 RNA-guided nuclease system, provide technologies for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
